Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study

Jensterle, Mojca; Ferjan, Simona; Vovk, Andrej; Battelino, Tadej; Rizzo, Manfredi

doi:10.1016/j.diabres.2021.108935

Cited by 16 publications

(47 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 28 studies were reviewed in full text, excluding trial registration records, duplicates of reporting, and non-English literature. Subsequently, eight studies involving 4,567 participants ( Wilding et al, 2021 ; Wadden et al, 2021 ; Rubino et al, 2021 ; Rubino et al, 2022 ; O'Neil et al, 2018 ; Friedrichsen et al, 2021 ; Hjerpsted et al, 2018 ; Jensterle et al, 2021 ) were included in the meta-analysis. The flow diagram of literature retrieval is displayed in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…The baseline characteristics of included studies are summarized in Table 1 . All eight studies were conducted on non-diabetic obese patients with an average baseline BMI of 33.8–40.1 kg/m 2 , and the individuals were all adults over 18 years of age ( Wilding et al, 2021 ; Wadden et al, 2021 ; Rubino et al, 2021 ; Rubino et al, 2022 ; O'Neil et al, 2018 ; Friedrichsen et al, 2021 ; Hjerpsted et al, 2018 ; Jensterle et al, 2021 ). Only one study included obese women with polycystic ovary syndrome ( Jensterle et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

“…All eight studies were conducted on non-diabetic obese patients with an average baseline BMI of 33.8–40.1 kg/m 2 , and the individuals were all adults over 18 years of age ( Wilding et al, 2021 ; Wadden et al, 2021 ; Rubino et al, 2021 ; Rubino et al, 2022 ; O'Neil et al, 2018 ; Friedrichsen et al, 2021 ; Hjerpsted et al, 2018 ; Jensterle et al, 2021 ). Only one study included obese women with polycystic ovary syndrome ( Jensterle et al, 2021 ). Semaglutide was administered subcutaneously in the included eight studies, five of which were 2.4 mg/week ( Friedrichsen et al, 2021 ; Rubino et al, 2021 ; Wadden et al, 2021 ; Wilding et al, 2021 ; Rubino et al, 2022 ), two were 1.0 mg/week ( Hjerpsted et al, 2018 ; Jensterle et al, 2021 ), and one was 0.05, 0.1, 0.2, 0.3, or 0.4 mg/day with dose escalation every fourth week, as well as every second week in the fast dose escalation group (FE) ( O'Neil et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials

et al. 2022

View full text Add to dashboard Cite

Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a conventional anti-obesity drug systematically in obese or overweight patients without diabetes.Methods: The randomized controlled trials (RCTs) of semaglutide in obese or overweight patients without diabetes were retrieved from PubMed, Cochrane Library, EMBASE, and ClinicalTrials.gov from database inception until 2 May 2022. Data extraction and quality assessment of studies meeting the inclusion criteria were performed, and statistical analysis was conducted by Review Manager 5.3 and Stata 14.Results: Eight studies involving 4,567 patients were enrolled in the meta-analysis. Compared with placebo, semaglutide induced a significant body weight loss (MD: −10.09%; 95% CI: −11.84 to −8.33; p ˂ 0.00001), elicited a larger reduction in body mass index (MD: −3.71 kg/m2; 95% CI: −4.33 to −3.09; p ˂ 0.00001) and waist circumference (MD: −8.28 cm; 95% CI: −9.51 to −7.04; p ˂ 0.00001), achieved weight loss of more than 5, 10, 15, and 20% with a higher proportion of participants. Semaglutide exhibited a positive effect on blood pressure, C-reactive protein, and lipid profiles, expressed more adverse effects than placebo, mainly gastrointestinal reactions. The results were stable and reliable with dose-dependence.Conclusion: Semaglutide indicated a significant weight loss with an acceptable safety for obese or overweight patients without diabetes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials

et al. 2022

View full text Add to dashboard Cite

show abstract

“…62 Semaglutide decreased tongue fat tissue and fat proportion (a possible early marker of body fat deposition) compared to placebo, when given in a weekly dose of 1 mg during 16 weeks, in 25 obese women with PCOS. 63 The Treating PCOS With Semaglutide vs Active Lifestyle Intervention (TEAL) trial is active and is recruiting individuals with PCOS and obesity. 64 Participants in this study will be randomized to receive either oral SEMA (3 mg or 7 mg once daily) for 4 months or dietary modification.…”

Section: Semaglutidementioning

confidence: 99%

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

Papaetis¹,

Kyriacou²

2022

Adv Clin Exp Med

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a disorder that involves several organ systems and cellular pathways. It is strongly influenced by environmental and epigenetic factors. The principal goal of all therapeutic approaches to individuals with reproductive abnormalities is the treatment of subfertility or the regulation of menstruation when pregnancy is not desired. Obesity is closely related to insulin resistance (IR) and subsequent hyperinsulinemia, which aggravate hyperandrogenism and impair early follicle development. Weight loss is of vital importance for overweight/obese individuals with anovulatory infertility. The GLP-1R agonists have achieved remarkable weight reduction and abdominal fat loss in patients with type 2 diabetes (T2D), as well as in overweight/obese individuals and individuals with prediabetes. They have also been shown to promote lower fasting insulin levels and insulin resistance markers. These beneficial effects have been suggested to be particularly helpful in women with PCOS, while their possible role in the hypothalamic-pituitary-gonadal axis is under intense research. This review analyzes the current evidence for GLP-1R agonists, focusing on their effects on ovarian morphology, menstrual dysfunction and fertility outcomes. It also discusses their future role in achieving targeted therapeutic approaches.

show abstract

“…Despite the availability of several GLP-1RAs, exenatide and liraglutide are the only two GLP-1RAs that have been systematically studied so far. The first results with the most potent long-acting GLP-1RA for the treatment of obesity, subcutaneous (s.c) semaglutide, that safely produces ≥10% of placebo-subtracted weight loss and ≥15% weight loss in more than half of the treated patients [ 10 ], have been reported only in one pilot study with a PCOS population [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Jensterle

Herman

2022

Biomedicines

Self Cite

View full text Add to dashboard Cite

Despite the continuous effort to understand the pathophysiology and determine potential therapeutic targets, PCOS treatment largely depends on lifestyle intervention and symptomatic management of individual signs and symptoms. International guidelines recognize the importance of weight reduction as a cornerstone for the achievement of better metabolic, reproductive, and cardiovascular outcomes in PCOS women who are overweight or obese. With its profound weight loss potential in patients with or without diabetes, the administration of GLP-1 receptor agonists has been investigated in overweight/obese women with PCOS in several single-center randomized control trials with considerable variation in the dosing regimen, follow-up duration, and outcome measurements over recent years. Most trials reported superior weight loss effects of GLP-1 receptor agonists compared to lifestyle changes or metformin, with additional metabolic, reproductive, and cardiovascular benefits in this population. However, their use is currently not widely accepted by the clinical community that treats this population. The major concern is how to balance the reproductive and metabolic treatment strategies since the use of GLP-1 receptor agonists requires effective contraception while on therapy and a washout period before pregnancy. Both approaches are not mutually exclusive, yet the best choice requires a careful assessment of the clinical context. Knowing a patient’s individual circumstances, precise clinical sub-phenotyping, and regular monitoring are crucial components for the safe and effective use of these new tools. In the present narrative review, we explore the current clinical evidence and provide the future perspectives and challenges for their implementation in PCOS management.

show abstract

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study

Cited by 16 publications

References 13 publications

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Contact Info

Product

Resources

About